"This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI," Demis Hassabis, Isomorphic Labs founder and chief executive, said in a statement.